Introduction
Few areas of research have raised as much interest and introspection, not to mention false hopes, as gene therapy. Indeed, few areas can have induced the editorial writers to wax quite so lyrical (Verma, 1994; Leiden, 1995; Blau et al., 1997) . The possibility of using DNA as a therapeutic tool first became theoretically feasible as a result of the advances in recombinant DNA technology which have revolutionized biological research in the last two decades. With the isolation and cloning of the genes responsible for inherited monogenetic disorders such as cystic fibrosis (Riordan et al., 1989; Rommens et al., 1989) , Lesch-Nyhan syndrome (Brennand et al., 1983; Melton et al., 1984) and adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID) (Orkin et al., 1983) theoretical cures could be achieved by the introduction and expression of a normal functional copy of the faulty gene in the appropriate tissue. However, the practical requirements for such gene therapy to be successful are formidable. After the gene has been isolated, its regulatory sequences must also be identified to ensure that expression of the transgene occurs in the appropriate tissue and at the appropriate time. Secondly, practical ways have to be found of delivering the gene to the appropriate organ and, finally, once expression is achieved, it must continue indefinitely, to obviate the requirement for multiple and repeated treatments. Perhaps not surprisingly, initial clinical trials of gene therapy in cystic fibrosis (Knowles et al., 1995) and ADAdeficient SCID (Blaese et al., 1995) have met with very limited success.
At a superficial level, cancer is an even less attractive candidate for gene therapy than either cystic fibrosis or ADA-deficient SCID: the progression from normal tissue to invasive malignancy may involve up to six or more separate genetic events (Bodmer, 1994) , all of which would, in theory, have to be corrected in order to reverse the malignant phenotype. Similarly, it would also be necessary to restore normal gene function to 100 per cent of the cells within a tumour population, which is impractical with current vector technology. However, novel gene therapy strategies for cancer have evolved that do not rely on gene replacement, and which thus circumvent some, but by no means all, of the difficulties listed above.
There are three main areas of interest to cancer gene therapists; gene delivery and the development of vectors that can achieve a high degree of gene transfer in vivo; the mechanisms by which cancer cell death can be achieved; and routes to selective delivery and expression of transgenes within specific target cell populations. The principal difficulties at present, and for the foreseeable future, are those of gene delivery. The shortcomings of current vector technology impose severe constraints on what is achievable and thus make greater demands upon the effector mechanisms of cancer cell death. Nonetheless, great advances have been made towards practical gene therapy for malignant disease, the principles of which are reviewed here. 
Methods of gene delivery
There are many potential methods by which DNA can be inserted into target cells, listed in Table I .
Viral vectors
Many types of virus have been employed as vectors for gene therapy, but adenovirus, retrovirus, adeno-associated virus and herpes simplex virus predominate. The ideal viral vector is replication deficient, can carry large amounts of therapeutic DNA, can infect a wide range of target cells, regardless of the replication status of those cells, are stable in human serum, are non-toxic and do not elicit inflammatory or immune responses in the host. The ideal viral does not exist, and each of the viruses described below meets some, but not all of these criteria.
Adenoviral vectors.
Replication-deficient adenoviral vectors can carry up to 10 kb of therapeutic DNA, which replaces the El and/or E3 regions of the adenoviral genome, which are essential for replication. These functions are provided by the packaging cells in which the virus is propagated. One advantage of adenoviral vectors is that they can be produced at very high titre: it is relatively easy to produce 10 10 infectious units per ml. Another advantage is that adenoviruses can infect cells regardless of their replication status, but the vectors do not integrate into the host DNA, remaining episomal, with the result that gene expression is transient. These features suggest that adenoviruses may be most suitable for therapeutic strategies where long-term gene expression is not required. If expression were required over an extended period repeated administration of the adenoviral constructs would be required, which may lead to the development of an inflammatory response by the host.
Other potential problems include the fact that repeated administration invariably leads to elevated titres of neutralizing antibodies, which could lead to the rapid elimination of the viruses on second administration. Also of concern is the potential for complementation by the wild-type virus if the patient has an adenoviral infection at the time of treatment, which could lead to the formation of replication competent vectors.
A new generation of adenoviral vectors has recently been developed which attempts to address the problems of the limited insert capacity and the production of immunogenic viral proteins. These so called 'gutless' vectors can package up to 30 Kb of foreign DNA and contain no viral genes (Kochanek et al., 1996) , with all the necessary viral functions being provided by the propagating cell line and a helper virus.
Retroviral vectors.
Most retroviral vectors are based upon the Moloney murine leukaemia virus (MoMLV) and are produced by replacing the structural viral genes (gag, pol and env) with recombinant DNA. The structural functions are provided by producer cells which contain these structural genes on separate plasmids that lack ip, the viral packaging signal to ensure that these genes cannot themselves be packaged into viral particles. MoMLV-based viruses will only infect actively dividing cells, but provide the advantage of stable gene expression from an integrated proviral genome. This potentially provides long-term expression, for which reason retroviruses may be best employed in ex vivo approaches to gene therapy. The site of incorporation of the viral DNA into the host genome is essentially random, leading to concerns that the integrated DNA may disrupt important cellular genes or activate potential oncogenes. However, as experience with these vectors has accumulated, it is now believed that these risks are extremely low.
One of the main concerns with retroviral vectors is the appearance of replication-competent viruses (RCR), which were discovered during characterization of early versions of producer cell lines (Donahue et al., 1992) and arise due to recombination between the structural and therapeutic plasmids in the producer cell lines. New packaging cells, in which the viral structural genes are present on two separate constructs reduce the chances of recombination (Markowitz et al., 1988) , although there has been a report of RCR even with these novel packaging cells (Chong and Vile, 1996) .
The two main problems with retroviruses are the low titre and rapid inactivation of viruses by complement in human serum. The titre of most retroviral vectors is 10 6 infectious units/ml, which is approximately four orders of magnitude below that achievable with adenoviruses, although there are many strategies by which retroviruses can be concentrated up to 100 fold to increase their titre. To reduce the lysis of virions by human complement, a so-called fourth generation of packaging cells have been developed, which are based upon human rather than murine cells (Cosset et al., 1995) .
Adeno-associated virus (AAV).
AAV is a single-stranded DNA parvovirus that can only replicate when complemented by adenovirus or herpes virus. In the absence of these helper viruses, it integrates into chromosomal DNA preferentially at a defined region on chromosome 19. Integration is possible into non-replicating cells but is more efficient in the S-phase of the cell cycle. It has been demonstrated that the transduction efficiency of immortalized cells with AAV was 50 times greater than transduction of primary cells (Halbert et al., 1995) , a feature which may give a degree of tumour specificity to a gene therapy protocol. AAVs are currently being used as vectors in two clinical trials in the USA, to introduce the gene for interleukin-2 (IL-2) into ovarian and prostate tumour cells.
Tumour cell
Non-transduced tumour cell 
Herpes simplex virus (HSV).
Early reports using replication-compromised HSV as a vector for gene therapy demonstrated significant toxic effects on infected cells precluding their use in human gene therapy trials. However, a mutant HSV (HSV-1716) which is deficient in the neuro-virulence factor ICP34.5 has been identified that will not replicate in neural tissue, but which appears to replicate in tumour cells, resulting in cell lysis (McKie et al., 1996) . This suggests that HSV may now be appropriate for use in gene therapy protocols as a combined gene delivery vector and tumour specific cytolytic virus (vide infra). Intraperitoneal injection of HSV-1716 into SCID mice bearing xenografts of human malignant mesothelioma cells reduced tumour burden and prolonged survival compared to control groups. No spread of virus outside the intraperitoneal cavity was observed suggesting that HSV-1716 may be suitable for the treatment of localized human tumours (Kucharczuk et al., 1997) .
Non-viral methods of gene delivery
The efficiency of gene transfer in non-viral methods is significantly less than can currently be achieved by viral transfer. Nonetheless, research in this area is intense as there are potential benefits of non-viral methods of gene delivery. The problems of immune responses against the viral vectors and unintentional replication and spread of viral vectors would be eliminated and there are less restrictive size restraints on the DNA inserted into the cell. Moreover, non-viraJ methods Jend themselves readily to the stringent manufacturing criteria that would be required for large scale production. Some cells can take up naked DNA following direct injection or electroporation. DNA can also be introduced into cells by bombardment with DNA-coated gold particles or complexing the DNA with cationic lipids. Liposome-mediated and receptor-mediated gene transfer are the physical methods most likely to be applicable to clinical use. The main disadvantages of liposome-mediated transfection are very low efficiency of gene transfer and the toxicity caused by the lipid components, but this may be reduced to some extent by altering the composition of the lipids used. The cationic lipid DOTAP (N-[l-(2, 3-dioloyloxy) propyl]-N, N, N-trimethylammonium methylsulphate) is currently being assessed in a phase I clinical trial using liposome-mediated transfer of the cystic fibrosis transmembrane regulator (CFTR) gene for the treatment of cystic fibrosis (McLachlan et al, 1996) .
Gene therapy strategies (1) Restoration of tumour suppressor gene expression
Rather than attempting to replace the function of all defective genes within a tumour, which is clearly impractical, it may be possible to induce apoptosis by the replacement of lost or mutated single tumoursuppressor genes, cellular proto-oncogenes or DNA repair genes. Examples which would be appropriate for gene therapy intervention include the tumour suppressor gene p53 (Takahashi et al., 1992; Brambilla et al., 1993) . Cellular concentrations of p53 increase after chromosomal damage, growth-arresting the cell and preventing it from entering mitosis. If the cellular damage cannot be repaired apoptosis is initiated (Liu et al, 1994) . Of the one miJJion new cancer cases diagnosed annually in the USA, 50 per cent are thought to carry a mutation in the p53 gene. The presence of a mutant p53 gene has been correlated with disruption of apoptosis, reduced cell cycle arrest and increased resistance to radiotherapy. Adenoviral vectors have been used to introduce wild-type p53 genes into radiation-resistant squamous cell carcinomas of the head and neck (SCCHN) both in vitro and in vivo. Replacement of wild-type p53 restored the Gl block and initiated apoptosis in vitro and sensitized SCCHN xenografts to radiotherapy in a nude mouse model Pirollo et al, 1997) .
(2) Prodrug-activating enzymes
Virus-directed enzyme prodrug therapy (VDEPT) is based on the introduction into a cell (using viral vectors) of a gene encoding a foreign enzyme which converts a relatively non-toxic agent (the prodrug) into an active cytotoxic compound, which kills the cells in which it has been made. The process of VDEPT is represented in Figure 1 .
Several enzymes have been used including herpes simplex virus thymidine kinase (HSV-TK) and E. coli derived cytosine deaminase (CD) and nitroreductase (NTR). HSV-TK phosphorylates the antiviral agent ganciclovir (GCV) to an intermediate (ganciclovir monophosphate) which is then phosphorylated by cellular enzymes to ganciclovir triphosphate, a potent inhibitor of DNA synthesis (Moolten, 1986) . Cells expressing HSV-TK are extremely sensitive to ganciclovir whereas nonexpressing cells are resistant leading to a large therapeutic index.
CD converts the non-toxic prodrug 5-fluorocytosine (5-FC) to the cytotoxic agent 5-fluorouracil (5-FU) (Haskell, 1990) whilst NTR (Anlezark et al, 1992) reduces the non-toxic prodrug CB1954 (5-[aziridin-l-yl]-2,4-dinitrobenzamide) to a powerful bifunctional alkylating agent (5-[aziridin-l-yl]-4-hydroxylamino-2-nitrobenzamide) (Knox et al, 1988 ). An important feature of the enzyme-prodrug approach is the so-called 'bystander effect' by which active drugs can diffuse from transduced cells containing the activating enzyme, causing the death of untransduced cells in the vicinity (Knox et al, 1988) . This is a very important phenomenon as it obviates the requirement that every tumour cell be transduced, which is very unlikely with current vector technology.
An adenoviral vector containing HSV-TK has been used to transduce human SCCHN cell lines in vitro, increased sensitivity to GCV was observed in cells expressing HSV-TK (Goebel et al, 1996) . This approach has also been used in a nude mouse model. Human SCCHN were grown as xenografts on both flanks and the tumours on the left flank treated with GCV. Complete regression of the HSV-TK infected tumours and partial regression of the tumours on the collateral flank was observed after administration of GCV. This study clearly demonstrated that both local and distant bystander effects occurred, and suggests that this therapy would be useful in the treatment of head and neck cancer.
(3) Immunological approaches
The development of a tumour vaccine which would provoke an immune response specifically directed against tumour cells is an attractive proposition for cancer therapy (Pardoll, 1993) . Systemic immune stimulation with high dose interleukin-2 (IL-2) is highly toxic and with limited efficacy (Sivanandham et al, 1992; Dillman, 1994) due in part to the short half-life of the protein. Tumour necrosis factor alpha (TNF a) produces marked antitumour responses in mice but has been disappointing clinically, due to the toxic effects of TNF a in man at concentrations greater than 500 mg/m 2 which is at least 10-fold lower than the dose tolerated by mice (Lejeune et al, 1994) . The anti-tumour immune response of the host can be improved by modification of tumour cells to express cytokines such as IL-2, IL-4, TNF a, interferon y or granulocyte-macrophage colony-stimulating factor (GM-CSF). The expression of such cytokines within transduced tumour cells would lead to increased local cytokine production, which may increase immunogenicity, provoke a systemic immune response which may aid in the destruction of circulating tumour cells, thereby reducing metastatic potential, and give an improved clinical response. Enhanced expression of major histocompatibility (MHC) class I and II molecules on tumour cells can also be achieved by over-expression of cytokine genes or direct transfection of MHC genes (James et al, 1991) . In animal models non-immunogenic tumours have been engineered to express cytokines or members of the MHC and stimulation of an immune response observed (Dranoff et al, 1993; Plautz et al, 1993) . Several investigators have inserted the IL-2 gene into animal tumours that after implantation have conferred antitumour immunity to the host (Gansbacher et al, 1990; Connor et al., 1993) . Tumour infiltrating lymphocytes (TILs) could serve as a good delivery system of IL-2 to human tumours; the rationale being that the active secretion of IL-2 in the vicinity of the tumour could increase the number of cytotoxic T cells against the tumour and reduce systemic toxicity (Kasid et al, 1990; Culver et al, 1991) .
The combination of IL-2 and HSV-TK gene therapy has been tested in a syngeneic animal model of head and neck cancer. C3H and HeJ murine squamous carcinoma cells were implanted into the floor of the mouth of mice. Adenoviruses expressing HSV-TK and murine IL-2 (mIL-2) were injected into the tumours and animals treated with GCV (25 mg/kg) twice daily for six days. Animals receiving TK alone or TK + mIL-2 demonstrated significant tumour regression compared to mIL-2 alone or control animals. However a syngeneic effect of the combination treatment was observed as the mice treated with the combination of TK + mIL-2 showed a greater regression of tumours compared with those treated with TK alone (O'Malley et al, 1997) . No cytotoxic effects of IL-2 were observed suggesting that this combination therapy may provide a new regimen for the treatment of human head and neck cancers. 
Gene targeting
The key to cancer gene therapy is the targeted delivery and expression of therapeutic DNA to a specific tumour cell population and a variety of strategies exist to achieve this.
(1) Selective delivery of therapeutic genes to tumour cells (a) Ex vivo delivery. At present, the optimal protocol for targeted gene delivery is the removal of tumour cells from the patient, retroviral transduction in vitro, followed by administration of the genetically modified cells back into the patient. This ex vivo approach is only really applicable for 'cancer vaccine' type strategies. There have been reports that re-introduced melanoma cells engineered ex vivo to express granulocyte-macrophage colony stimulating factor (GMCSF) are capable of generating a generalized anti-melanoma immune response (Dranoff et al., 1997) .
(b) In vivo regional delivery.
Crude, but surprisingly effective, targeting can be achieved by simply injecting vectors directly into tumours. Examples include administration of recombinant viruses directly into endobronchial lesions accessible by bronchoscopy (Roth et al., 1996; Tursz et al., 1996) and stereotactic injection of retroviral producer cells into malignant brain tumours (Kun et al., 1995) . However, this technique is never likely to demonstrate anything more than a proof-ofprinciple.
It is possible to exploit the fact that some tumours are localized to specific body cavities (e.g. ovarian cancer) or are served by a specific blood supply (e.g. hepatic metastases from colorectal cancer), such that regional perfusion with therapeutic constructs/ viruses could greatly enhance organ and tumour specificity. The principle of direct intra-arterial chemotherapy for hepatic metastases from colorectal cancer has been explored (De Takats et al., 1994) and there are reports of tumour targeting via injection into the portal vein (Hurford et al., 1995) .
(2) Selective uptake mechanisms
At a crude level, the selective integration of retroviruses into actively dividing cells can be utilized to introduce genes into replicating tumour cells, but not quiescent neighbouring normal cells (Culver et al., 1992) . Another example of targeted gene delivery is the use of specific cell surface receptors. This approach requires that the natural tropism of a viral vector be modified so that it will only infect specific cell populations. For example, it is possible to redirect the binding of adenoviral vectors to specific tumour cell types by the use of bidirectional antibodies that bind both to the fibre protein of the adenovirus and markers on the tumour's cell surface, such as fibroblast growth factor (Goldman et al., 1997) .
(3) Selective gene expression via tumour or tissue specific promoters
By linking the expression of therapeutic constructs to tumour or tissue-specific promoters, it may be possible to limit gene expression to tumour cells. The use of promoters relies on the fact that tumour cells frequently over-express certain genes, such as carcinoembryonic antigen (CEA) in colorectal carcinoma or prostate-specific antigen (PSA) in prostate carcinoma. Table II lists some of the tumour or tissue specific genes that have been identified. Once the promoters of tumour specific antigens have been fully mapped and characterized, it may be possible to construct synthetic promoters which contain binding sites for several tumour specific transcription factors thus providing a vector which could be used in multiple tumour types. Also, to achieve expression of therapeutic genes in primary tumours and metastases, the administration of several constructs or the production of vectors containing two or more promoters may be required.
(4) Tumour-specific mechanisms Tumour restricted cytolytic viruses.
In addition to the 1716 mutant herpes simplex virus type I mentioned earlier, adenoviral vectors have been developed that will only replicate in tumour cells. p53 mediates cell-cycle arrest and apoptosis in response to DNA damage. DNA tumour viruses encode proteins which inactivate p53 and allow efficient viral replication (Debbas and White, 1993) . The dll520 (ONYX-015) virus is an adenovirus in which the gene for the 55 kD protein which binds to and inactivates p53, has been deleted from the E1B region (Bischoff et al., 1996) . Normal human cells are highly resistant to ONYX virus whereas tumour cells containing p53 abnormalities show replication-dependent cytopathic effects when infected. Antitumoural effects of intratumoural injections of ONYX virus have been observed in nude mice with C33A (cervical carcinoma) and HLaC (laryngeal carcinoma) xenografts (Heise et al., 1997) . The efficacy of the ONYX virus plus chemotherapy using cisplatin or 5-fluorouracil has been shown to be significantly greater than either agent alone, and this regimen is currently being used in Phase I clinical trials for the treatment of ovarian and head and neck tumours.
Conclusions
The majority of the trials are still at the phase I stage and results have not been fully published. Preliminary findings have not all been encouraging, although most protocols appear to be safe with few adverse side-effects being reported. It is far too early to assess the therapeutic efficacy of gene therapy; as most of the trials involve patients with advanced disease and major difficulties lie in adapting effective in vitro approaches to clinical trials, usually due to poor gene transfer in vivo. Careful monitoring of the scientific endpoints regardless of the clinical results is essential to interpret findings and allow the refinement of strategies and vectors. In the USA, a National Institutes of Health panel has provided recommendations regarding future gene therapy trials and three key areas of research have been identified. The first is the refinement of vectors and an understanding of the vector-host interactions. Vectors need to be improved to maintain an adequate level of cell-specific or tissue-specific gene expression. The second is to increase the basic understanding of disease pathogenesis and pathophysiology to aid the development of new treatment strategies. The final recommendation is the development of appropriate animal models in which to test strategies prior to clinical trials, as some phase I trials have been established on the basis of little data from animals.
The number of gene therapy protocols and clinical trials is increasing rapidly and, with a better understanding of the basic scientific principles involved, the data obtained over the coming years should determine whether gene therapy provides a significant advantage over traditional methods of treatment and which approaches and methods of gene delivery will be most beneficial.
